Abstract
Abstract Cancer and autoimmune disease lead to illness by damaging and evading a patients natural defenses. Immunotherapy methods are designed to reclaim and bolster the immune system to treat disease. This requires both highly specific binding of therapeutic agents to target molecules and optimizing techniques to harness the effector functions of the immune system. We describe methods for both these requirements. These include cell based systems for improving attachment to targets by assaying binding of therapeutic antibodies to immune checkpoint receptors and displaying molecular targets to CAR- T cells. They also include assays to improve immune effector functions such as Antibody-dependent cell-mediated cytotoxicity (ADCC) through cell based assays of IgG Fc binding to FCgRs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
